REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today ...

MUMBAI: The Maharashtra Pollution Control Board (MPCB) has shut down 10 ready-mix concrete (RMC) plants and recovered Rs 84 lakh in penalties during inspections carried out over the past two days ...

Mumbai: The Maharashtra Pollution Control Board (MPCB) has shut down 10 ready-mix concrete (RMC) plants as part of a crackdown on air pollution and recovered Rs 84 lakh in penalties during inspections ...

Finland's RMC to Build Two Icebreakers for the US Coast Guard By Soren Jeppesen COPENHAGEN, Dec 30 (Reuters) - Finland's ‌Rauma Marine Constructions has signed ‌a deal to build two icebreaker ships ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Moffitt Cancer Center researchers report the first clinical activity of a RAS inhibitor in patients with NRAS-mutant melanoma. The investigational drug daraxonrasib (RMC-6236) and its preclinical ...

After logging more than 100 million all-electric miles with deployed fleet of battery-powered semi trucks, Volvo’s latest EV milestone can be found OFF the highway: the company’s new L90 Electric ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A new-to-market Georgia ...

Milford Police said it was by chance that no one was killed when an out-of-control 30-ton piece of construction equipment careened down a hill on Friday, Aug. 15, and crossed one of the busiest ...

Imagine this: you’re in the middle of an important project, juggling deadlines, and collaborating with a team scattered across time zones. Suddenly, your computer crashes, and hours of work vanish in ...

Daraxonrasib received FDA breakthrough therapy designation for metastatic PDAC with KRAS G12 mutations, expediting its development. The designation is based on promising phase 1 trial results, with ...